LEGN - Legend Biotech Corporation

-

$undefined

N/A

(N/A)

Legend Biotech Corporation NasdaqGS:LEGN Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Location: 2101 Cottontail Lane, Somerset, NJ, 08873, United States | Website: https://www.legendbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

10.02B

Cash

1.005B

Avg Qtr Burn

-65.83M

Short % of Float

4.65%

Insider Ownership

1.33%

Institutional Own.

47.77%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details
Blood cancer, Cancer, Multiple myeloma

Approved

Quarterly sales

CARVYKTI (cilta-cel) Details
Blood cancer, Cancer, Multiple myeloma

Approved

Quarterly sales

Phase 3

Data readout

LB2102 Details
Cancer, Small cell lung cancer

Phase 1

Data readout

LB1901 Details
Cancer, T-cell lymphoma

Failed

Discontinued